| abstract |
PURPOSE: The titled pharmaceutical, prepared by adding an adequate amount of a plasminogen inhibitor to an aqueous solution containing the plasminogen or dried powder thereof, and useful for the remedy of thrombosis, etc. n CONSTITUTION: A plasminogen pharmaceutical, prepared by adding a plasminogen inhibitor, e.g. ε-aminocaproic acid (EACA), lysine, phenylmethanesulfonyl fluoride (PMSF) or aprotinin, in an amount effective for stabilizing the plasminogen to an aqueous solution containing the plasminogen or dried powder thereof, and having improved stability. The higher effective concentration of the stabilizer provides a greater stabilizing effect in the case of EACA, lysine, etc. The concentration is 0.001W5%W/V for the aqueous solution and 0.01W10%W/W for the powder. It is important to add the PMSF, aprotinin, etc. in an amount enough to inhibit the plasmin present completely to the aqueous solution of the plasminogen or dried powder thereof. n COPYRIGHT: (C)1982,JPO&Japio |